Key Points
- Insider sale: Director Brian Daniel Webster sold 15,000 shares on April 15 at an average price of $20.04 for $300,600, cutting his stake by 4.11% to 349,786 shares — his third recent sale after 15,000-share disposals on March 17 and February 17.
- Company performance and sentiment: KMTS trades around $20.41 with a $1.19B market cap; the company posted a Q of ($0.61) EPS (missing estimates), revenue up 62.7% YoY but steep losses (net margin -171.9%, negative ROE), and analysts are mixed (consensus Hold, average target $27.40; Goldman lowered its target to $17 while BTIG rates it Buy at $32).
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of the business's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00. Following the transaction, the insider owned 349,786 shares in the company, valued at approximately $7,009,711.44. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Brian Daniel Webster also recently made the following trade(s):
- On Tuesday, March 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.27, for a total value of $304,050.00.
- On Tuesday, February 17th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00.
Kestra Medical Technologies Price Performance
Shares of NASDAQ:KMTS opened at $20.41 on Friday. The stock has a market capitalization of $1.19 billion and a P/E ratio of -5.15. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The business has a 50-day moving average of $22.23 and a two-hundred day moving average of $24.29. Kestra Medical Technologies, Ltd. has a fifty-two week low of $13.25 and a fifty-two week high of $30.00.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million during the quarter. The business's revenue for the quarter was up 62.7% on a year-over-year basis.
Institutional Investors Weigh In On Kestra Medical Technologies
Hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its holdings in Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company's stock worth $115,878,000 after buying an additional 2,529,851 shares during the period. Brown Advisory Inc. grew its position in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company's stock valued at $44,775,000 after acquiring an additional 428,996 shares during the period. Alliancebernstein L.P. increased its position in Kestra Medical Technologies by 13.7% during the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company's stock worth $35,449,000 after buying an additional 179,885 shares during the last quarter. Eventide Asset Management LLC lifted its stake in shares of Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company's stock worth $33,671,000 after buying an additional 65,288 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in Kestra Medical Technologies by 180.8% in the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company's stock valued at $25,221,000 after acquiring an additional 612,343 shares during the period.
Analyst Ratings Changes
KMTS has been the topic of several research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a "neutral" rating for the company in a research note on Thursday, April 9th. Finally, BTIG Research reaffirmed a "buy" rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $27.40.
Check Out Our Latest Research Report on KMTS
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
